Evidence map›Paper›PMID 24287405›Full record

ArticleThe American journal of pathology2014

Critical role of the mTOR pathway in development and function of myeloid-derived suppressor cells in lal-/- mice.

Xinchun Ding, Hong Du, Mervin C Yoder, Cong Yan

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Lysosomal Acid Lipase in Lipid Metabolism and Beyond.Arteriosclerosis, thrombosis, and vascular biology · 2019
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xinchun DingDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana; Center for Immunobiology, Indiana University School of Medicine, Indianapolis, Indiana.
Hong DuDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: hongdu@iupui.edu.
Mervin C YoderHerman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.
Cong YanDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana; Center for Immunobiology, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: coyan@iupui.edu.
Indiana University Health · USIndiana University School of Medicine

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AMBER L. MOSLEY · 1999 to 2026
$59.3M
Pathophysiology of PPARgamma in the lungR01HL087001 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI DU, HONG · 2008 to 2012
$1.9M
Stat3 Downstream Genes as Lung Adenocarcinoma BiomarkersR01CA138759 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI YAN, CONG · 2010 to 2014
$1.8M
Inflammation and Immunosuppression in Lung CancerR01CA152099 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI YAN, CONG · 2011 to 2015
$1.5M
NCI NIH HHS CA138759NCI NIH HHS CA152099NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA138759NCI NIH HHS R01 CA152099NHLBI NIH HHS HL087001NHLBI NIH HHS R01 HL087001
6 · The paper itself

Abstract

Lysosomal acid lipase (LAL) is essential for the hydrolysis of cholesteryl esters and triglycerides to generate cholesterol and free fatty acids in cellular lysosomes. Ablation of the lal gene (lal(-/-)) systemically increased expansion of cluster of differentiation molecule 11b (CD11b), lymphocyte antigen 6G (Ly6G) myeloid-derived suppressor cells (MDSCs) that caused myeloproliferative neoplasms in mice. Study of lal(-/-) bone marrow Ly6G(+) MDSCs via transcriptional profiling showed increases in mammalian target of rapamycin (mTOR) signaling pathway transcripts. Injection of mTOR pharmacologic inhibitors into lal(-/-) mice significantly reduced bone marrow myelopoiesis and systemic CD11b(+)Ly6G(+) cell expansion. Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice. Pharmacologic and siRNA suppression of mTOR, regulatory-associated protein of mTOR, rapamycin-insensitive companion of mTOR, and Akt1 function corrected CD11b(+)Ly6G(+) cell in lal(-/-) mice development from Lin(-) progenitor cells and reversed the immune suppression on T-cell proliferation and function in association with decreased reactive oxygen species production, and recovery from impairment of mitochondrial membrane potential compared with control mutant cells. These results indicate a crucial role of LAL-regulated mTOR signaling in the production and function of CD11b(+)Ly6G(+) cells. The mTOR pathway may serve as a novel target to modulate the emergence of MDSCs in those pathophysiologic states in which these cells play an immunosuppressive role.

Indexed as

Signal TransductionAdaptor Proteins, Signal TransducingAnimalsAntigens, LyApoptosisBone Marrow CellsCarrier ProteinsCD11b AntigenCell ProliferationGene Knockdown TechniquesImmunosuppression TherapyMembrane Potential, MitochondrialMiceMyeloid CellsPhosphorylationProto-Oncogene Proteins c-aktAdaptor Proteins, Signal TransducingAntigens, LyCarrier ProteinsCD11b AntigenLy6G antigen, mouselysosomal acid lipase, mouseProto-Oncogene Proteins c-aktRapamycin-Insensitive Companion of mTOR ProteinReactive Oxygen SpeciesRegulatory-Associated Protein of mTORrictor protein, mouseRptor protein, mouseSirolimusSTAT Transcription FactorsSterol EsteraseTOR Serine-Threonine Kinases

Identifiers

PMID24287405
PMCPMC3906486
OpenAlexW2007800148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.